



Oncidium  
foundation

IMPACT  
REPORT  
2024

**Striving for equal access to  
Radioligand Therapy for cancer  
care for everyone, everywhere**

# Introduction

This year has been transformative, marked by profound stories of resilience, hope, and the life-changing impact of our initiatives. Our work continues to make a significant difference in the lives of patients worldwide, including individuals like Fernando Acosta.

Fernando's journey embodies the core of our mission. Diagnosed with a challenging prostate cancer condition, he faced numerous challenges. Yet, with the support of his medical team, legal advisors, and the Oncidium foundation, Fernando found new hope and strength. His story is a powerful example of how unity and collaboration can create accessible healthcare, reflecting the dedication of a community.

His experience highlighted the critical role of patient experience and its impact on the development of treatment options. His inspiring story played a key role in the launch of one of our major initiatives this year: the RLT-connect platform, a collaborative platform that facilitates access to treatment for patients in need.

At the age of 55, I was diagnosed with advanced Prostate Adenocarcinoma Gleason 9, following an abrupt onset of complications. After enduring 42 sessions of chemotherapy and intensive radiotherapy, I felt there was nothing left to try. As a man of science, I have always focused on resilience and moving forward.

When I discovered Lutetium-177-PSMA, I was determined to make it happen. To obtain Argentinian social security reimbursement, I gathered 70,000 signatures and collaborated with scientists and lawyers to turn the impossible into reality. I never doubted its effectiveness. Thanks to the Oncidium foundation, I was able to obtain this treatment. After three doses, scans showed no evidence of active neoplastic cells, bringing tears of joy to my eyes and those who supported me.

Today, I lead a group of patients undergoing Lutetium-177 PSMA treatment. I am eternally grateful to the scientists who discovered this radionuclide, the Oncidium foundation, and my treating physician, Dr. María Bastianello, for their humanity and dedication.

**Fernando Acosta,** who inspired the RLT-Connect project



# INDEX

<b>The Onci-Word</b>	<b>1</b>
<b>Oncidium Foundation Genesis</b>	<b>2</b>
<b>Our CEO's Journey</b>	<b>5</b>
<b>Presenting the Foundation</b>	<b>6</b>
Our Mission - Vision - Pillars	
Recognizing our First Supporters	
Board of Directors	
Scientific Board	
Operational Team	
<b>Those We Serve</b>	<b>14</b>
Audience	
<b>Key Pillars - Access</b>	<b>18</b>
Helping Patients Find Treatments	
Oncidium Foundation Ambassadors	
Enhancing Access	
<b>Key Pillars - Education</b>	<b>26</b>
Guidance for People Living with Cancer	
Resources for the Nuclear Medicine Community	
Education for Healthcare Professionals	
Awareness for Healthcare Professionals	
<b>Key Pillars - Hope</b>	<b>40</b>
Dose Donation Platform - RLT-Connect	
Supporting Research Projects	
Tackle Cancer Challenge	
<b>The Heart of Why We Act</b>	<b>50</b>
Patient Focus	
<b>Oncidium Foundation in numbers</b>	<b>54</b>
Let's talk about Finance	
Key Figures	

# Oncidium Foundation Genesis

In 1998, after over 15 years in various roles within the R&D and project management departments of conventional pharmaceutical industries, I ventured into the relatively unknown field of nuclear medicine by joining CIS bio (now Curium) as head of R&D. It was here, surrounded by a dedicated team, that I learned everything I needed to know about this transformative field. I quickly became convinced that nuclear medicine held immense potential in cancer therapy, and this conviction grew stronger with time.

By 2011, it was clear to me that radioligand therapy, an innovative approach using targeted radioactive isotopes to treat cancer, could revolutionize cancer care. While still early-stage, I was certain it could become a powerful tool in the fight against cancer, particularly for patients with few treatment options. This realization led me to create the Oncidium foundation with a clear mission: to increase awareness about radioligand therapy and make it

accessible to all, regardless of financial situation or geographical location. I knew from the start that the path would not be easy. The challenge was not only advancing the technology but also breaking down access barriers for patients worldwide. Too often, life-saving treatments remain out of reach for those who need them the most.

2019 was a major turning point for the foundation, thanks to a generous donation from Chris Behrenbruch and Andreas Kluge. This vital support enabled us to move from concept to action. The foundation was now equipped to recruit staff, launch initiatives, and, most importantly, tangibly improve patients' lives. I will always be grateful to Chris and Andreas for their belief in our vision and their critical role in helping us take the first steps toward real impact.

This report highlights the progress we have made since then, the lives we've touched, and the milestones we've achieved. But our work is far from done. My wish for the future remains unchanged: to save as many lives as possible by making radioligand therapy accessible to patients everywhere.

Together, we are building a future where cutting-edge cancer treatments are available to all and where every patient has the opportunity to receive the care they need.

**Richard Zimmermann,**  
President & Founder



## Why "Oncidium"?

The foundation was named by Dr. Zimmermann, inspired by his passion for orchids. In the plant kingdom, Orchids represent the pinnacle of evolution. The Oncidium genus of orchids is named after the callus at the flower's lower lip. Derived from the Greek word "onkos" (tumor), it indirectly refers to cancer (oncology).

A similar parallel can be drawn with radiotheranostics, which represents the highest level of development in drug manufacturing combining biology, chemistry and radiation.



# Our CEO's Journey

My journey with the Oncidium foundation began in 2019 when Dr. Richard Zimmermann asked me to take over the foundation's executive management.

With a career rooted in nuclear medicine, a field that captivates me, finding purpose in my work has always been a top priority. Oncidium's mission spoke directly to my heart.

I led the foundation part-time for five years while juggling my previous role, which was challenging yet immensely rewarding. Fortunately, I was supported by two exceptional individuals, Tala Allahham and Floriane Laurent, as we built everything from the ground up.

**Rebecca Lo bue,**  
Chief Executive Officer

It quickly became apparent that the global nuclear medicine community was eager to rally behind our cause, which was incredibly motivating. In just five years, we built a community of over 100 ambassadors and, most importantly, meaningfully impacted the lives of many affected by cancer. Our growing operational team, which now consists of 12 incredible team members deeply committed to making a difference, has accomplished significant milestones. In 2024, I decided to dedicate myself to the foundation fully.

Looking ahead, we are eager to advance our strong foundation and expand our global presence by reaching every country. As we undertake this journey, we are committed to maintaining the spirit of solidarity and community that defines our work, ensuring our focus is always on significantly improving the lives of cancer patients worldwide. ”

Our Mission - Vision - Pillars	8
Recognizing Our First Supporters	10
Board of Directors	11
Scientific Board	12
Operational Team	13

# Presenting the Foundation



# Our Mission - Vision - Pillars



## Vision

We envision a world where every individual affected by cancer can **access cutting-edge radioligand therapy**, experience an enhanced quality of life, and ultimately find hope, regardless of financial or geographic constraints.

We are united by a deep desire to ensure that no one faces their cancer journey alone. To this end, we have built a global community that supports those impacted by cancer.

Through innovative approaches and educational initiatives, we are working to transform cancer treatment, advance personalized theranostics, and redefine cancer care delivery.



## Mission

We have focused our daily efforts on four missions to extend our vision globally. Each mission is ongoing, continuously motivating us to reach our goals, with one crucial focus: **people living with cancer**.

- Enhancing global access to radioligand therapies and providing financial support for cancer patients in need.
- Providing education and resources to patients, caregivers, healthcare professionals, and the nuclear medicine community.
- Supporting research and development in radioligand therapy.
- Advocating for improved practices in cancer care.



## Pillars

Our mission and vision are built around three pillars that drive and shape our projects.

- Improving **Access** for radiotheranostics all around the world for patients and healthcare professionals.
- Advancing **Education** by providing educational materials for patients and healthcare professionals.
- Building **Hope** by creating connections and encouraging collaborations between the various stakeholders involved in cancer patient care.

# Recognizing Our First Supporters

The Oncidium foundation could not achieve its mission without our generous supporters. We want to express our deep appreciation to our initial benefactors for their unwavering belief in the foundation's purpose, enabling a transition from a cutting-edge concept to a tangible, active organization.

With their support, we successfully initiated our operational activities and have gained legitimacy within the nuclear medicine community in recent years, developing a global network of over 100 ambassadors and assisting many patients across the globe.

However, this is just the beginning. We are committed to growing our initiatives, helping more patients, building new partnerships, and creating long-term solutions that will positively impact global healthcare.



*“As the field of nuclear medicine grows in importance, there is a need for patient advocacy groups that are able to build awareness and connect patients to treatment options. This visionary idea motivated me to become an early participant in the creation of the foundation.”*

**Dr. Christian Behrenbruch** Co-founder, MD and CEO at Telix Pharmaceuticals



*“Observing the global momentum of radionuclide therapy, I felt the need to support the Oncidium foundation, as it strives to bridge gaps for a broader understanding of the existence and benefits of such options and brings us closer to our shared goal.”*

**Dr. Andreas Kluge** Owner, ABX-CRO Advanced pharmaceutical services and Pharmaceuticals Consultant, Co-founder at Telix Pharmaceuticals

# Board of Directors



**Richard Zimmermann, PhD, President & Founder**

Independent consultant in the Radiopharmaceutical field (Chrysalium Consulting, France), co-Founder of MEDraysintell, initiator of the Belgian rad4med.be network, co-founder of Global Morpho Pharma SARL (France) and Protherium (France).



**Eric van Walle, PhD, Vice-President**

Former Director-General SCK CEN (Studiecentrum voor Kernenergie – Centre d'Etude de l'Energie Nucléaire, www.sckcen.be), Mol and Brussels, Belgium.



**Bruno Scutnaire, Board Member**

Executive Vice-President at IBA RadioPharma Solutions, Louvain-La-Neuve, Belgium.



**Jérôme Majoie, Board Member**

CEO of the Foundation Fournier Majoie, a Belgian entity committed to empowering entrepreneurial efforts in the battle against cancer.

# Scientific Board

The Oncidium foundation is supported by a Scientific Board of international nuclear medicine experts who provide guidance on research and innovation. Their expertise ensures that our educational content, aimed at both patients and healthcare professionals, is scientifically accurate and clearly communicated.



■ **Dr. Alice Viana, PhD, Advisory Board Chair, Belgium**  
 Scientific Director at the Oncidium foundation. Alice leads all our scientific projects to ensure the accuracy of every piece of information we deliver.



■ **Prof. Meera Venkatesh, PhD, Member, India**  
 Nuclear Scientist with 40+ years work experience in the various applications of nuclear technologies. Now retired, still devoting her time to propagate the beneficial applications of nuclear technologies for humankind.



■ **Dr. Omar Yehia, MD, Member, Egypt**  
 Radiology and Nuclear medicine physician. Director of PET/CT units at Misr Radiology Center. First center in Egypt to provide Gallium-68 PET/CT scans and Lutetium-177 therapy (NET and prostate). Raise awareness on the value of radiotheranostics, to the public and physicians.



■ **Dr. Jeremie Calais, MD, PhD, Member, USA**  
 Associate Professor and Director of the Clinical Research Program of the UCLA Nuclear medicine and Ahmanson Translational Theranostics Division. He is a Certified Principal Investigator (CPI) by The Association of Clinical Research Professionals (ACRP) and conducts academic investigator-initiated and industry sponsored trials using targeted radionuclide imaging and therapy.



■ **Dr. Vasko Kramer, PhD, Member, Chile**  
 As head of R&D, Vasko is continually working on several new radiopharmaceutical developments and collaborating with other sites to help them get access to radioligand therapy (RLT).



# Operational Team

Based in Belgium, the foundation counts 11 full-time staff members. It brings a diverse range of profiles, all united by a shared goal: to help people living with cancer access the most accurate information and treatment options, regardless of their financial or geographical situations.



From left to right

- **Tala Allahham**, Head of Global Partnerships
- **Sybillie Vermeylen**, Executive Assistant
- **Floriane Laurent**, Public Relations Manager
- **Rebecca Lo bue**, Chief Executive Officer
- **Thais Rocha Ruda**, Communication Manager
- **Alice Viana**, Scientific Director
- **Camille Chapalain**, Partnership Manager
- **Dorian Buekenhoudt**, Communication Associate
- **Gauthier Roelants de Stappers**, Director of Finance & Administration
- **Shenlan Liu**, Administrative Assistant
- **Efrain Perini**, Foundation Development Director



# Those We Serve

People Living with Cancer	16
Healthcare Professionals	16
Nuclear Medicine Community	17





### People Living with Cancer

- **Who they are:** Individuals living with cancer, their families, caregivers, and those interested in understanding cancer treatment advancements.
- **Purpose:** To educate and raise awareness about radiotheranostics as a cutting-edge and effective cancer treatment option.
- **Focus:** Providing accessible information, sharing patient success stories, and emphasizing the benefits of radiotheranostics to inspire trust and hope.



### Healthcare Professionals

- **Who they are:** Oncologists, radiologists, surgeons, medical physicists, and other healthcare practitioners involved in cancer care.
- **Purpose:** To spread radiotheranostics in oncology and expand its integration into clinical practice.
- **Focus:** Delivering scientific updates, offering educational materials, and fostering collaboration to improve cancer care.



### Nuclear Medicine Community

- **Who they are:** Nuclear medicine researchers, technologists, industry professionals, and academic institutions specializing in radiotheranostics.
- **Purpose:** To support innovation, research, and development in nuclear medicine, particularly in the field of radiotheranostics.
- **Focus:** Promoting advancements in technology, fostering knowledge-sharing, and advocating for the wider application of nuclear medicine techniques in cancer care.

Those We Serve



# 1 Access Education Hope

# key pillars



Helping Patients Find Treatment	20
Oncidium Foundation Ambassadors	22
Enhancing Access	24

# Access

The proliferation of radiotheranostics in cancer care brings its own set of practical challenges. As we witness and support the development of new diagnostics and therapeutics for an ever growing number of indications, our foundation aims to broaden access so that cancer-affected individuals can be offered the best diagnoses and therapies they need, whenever and wherever they need them.

To bring this mission to life, we are investing in projects and collaborating with global experts, including our Oncidium Ambassadors Network whose deep understanding of the unique challenges and opportunities in their countries enables us to join forces in creating meaningful, lasting impact.

## Helping Patients Find Treatment

In the foundation's early days, we recognized that an essential tool for improving patient access to radioligand therapies for cancer care was missing – **a global map identifying centers already delivering these therapies.** This tool is accessible to all centers that wish to register and share information about current radiotherapeutics. It is also available to the general public, providing cancer-affected individuals with the location and contact details of the nearest hospital that can assess whether they may be candidates.

**Currently, more than 650 centers registered on our website.**

We work to update this list daily to support patients in finding the nearest center providing radioligand therapy.

The map is also used to find the most suitable center for their type of pathology. As each person is different, we need to give them the most accurate information possible for themselves, in their own language.

Find a therapy center: 

**+650**  
Registered  
Therapy Centers



Register your therapy center and help to improve patients' access

# Oncidium Foundation Ambassadors

## Global Perspective, Local Actions

This chapter introduces the Oncidium foundation’s Ambassadors – passionate experts bringing us considerable steps closer to our unifying objective: enhancing radiotheranostics awareness, availability, and access for people living with cancer.

### Ambassadors’ Mission


As radiotheranostics gains momentum, we have much to do before the technology can manifest its potential and be accessible to cancer patients. Realities, challenges, and opportunities will sometimes vary drastically from one country to another however, one crucial similarity stands out – there are determined individuals from various nationalities and areas of expertise eager to translate the idea of radiotheranostics into action.

Whether experienced or aspiring pioneers, our ambassadors are professionals with a strong foundation in various fields, including chemistry, pharmacy, medicine, biology, oncology, and nuclear medicine. They are typically actively engaged in the nuclear medicine, radiotheranostics, or radiopharmaceuticals sectors, bringing their expertise to the forefront of medical innovation and introducing new radiotherapeutics in their respective regions.



*New discoveries are being made every day on potential new treatments for patients with radiotheranostics. We are focusing with the Oncidium foundation on finding hope for people living with cancer all around the world. Many patients don't know about radiotheranostics, and I've dedicated my career as a pharmacist and radiochemist to clinical trials and ensuring patients can receive new treatment options. I am really happy to support these patients as fully as possible, not only in the United States but all over the world, alongside all the Ambassadors of the Oncidium foundation.*

**Dr. Jean-Luc Vanderheyden**  
Head of The Oncidium foundation USA



### Current Efforts, Future Vision

Ambassadors play a **crucial role** in suggesting and **identifying key projects** focused on **improving patient access, advancing education,** and supporting the development of radiotheranostics, ultimately **providing hope** for the field and for people who could benefit from them.

Our team of ambassadors is active in **45 countries,** with the goal of reaching every corner of the globe.

# Enhancing Access

We currently count on the support of 100 dedicated ambassadors representing 45 countries across five continents. They actively work to expand access to vital resources by building a robust ecosystem around patients and connecting radioisotope suppliers, radiopharmacies, oncologists, urologists, and other key stakeholders. Their efforts help ensure that patients have greater access to innovative radiotherapeutic treatments.

Looking ahead, our foundation's long-term goal is to onboard at least one ambassador in every country worldwide. Achieving this ambitious target will require increased investments in research, development, and access initiatives. The pioneering efforts of our current ambassadors will serve as a driving force, inspiring new recruits and ensuring the development of a global and lasting ecosystem.



AMBASSADORS MEETING 2024



2023



2022

“ At the time, when I first heard about the foundation, I was concerned because my patients didn't have access to these radiotheranostics, and it was really sad to send them back home without hope. That's why I joined the foundation: to help them get access to radiotheranostics ”

**Dr. Cecilia Carreras** Ambassador in Mexico



“ We have different ideas around the world. Alone, we can advance very slowly but together we can advance very quickly. That is what I really like in being an Oncidium ambassador. ”

**Dr. Alexia Daoust**, Ambassador in France



“ Being an ambassador for the Oncidium foundation in Brazil is one of the most significant roles of my professional career. Sharing information and improving access to theranostics in my country has allowed me to give back to my specialty, nuclear medicine, and the community that has supported me over the past 25 years. ”

**Dr. Guilherme Rossi** Ambassador in Brazil



“ The reason why I joined Oncidium is that I want to create and open more doors and navigate mainly access to therapy for patients in South Africa and Africa as a whole. I am very passionate about doing outreach work around cancer awareness, mostly to the rural community, because they don't have much access to nuclear medicine technologies in some parts of South Africa and Africa in general. I'm hoping that together we will be able to reach these areas and enhance access to radiopharmaceuticals for diagnosis and therapy. ”

**Dr. Phumudzo Nemataduni** Ambassador in South Africa



# Access 2 Education Hope

Guidance for People Living with Cancer	29
Ressources for Nuclear Medicine Community	34
Education for Healthcare Professionals	36
Awareness for Healthcare Profesionals	38



# Education

Our foundation's second core value is enhancing education and raising awareness. Providing accurate and up-to-date information deepens both patient and healthcare professional understanding of how these therapies work and their effectiveness for different cancer types, resulting in more personalized treatment and better patient care.
















The main objective of this pillar is to provide both patients and healthcare practitioners with essential knowledge. Each audience deserves tailored approaches, ensuring that everyone has access to the resources they need for informed decision-making.



## Guidance for People Living with Cancer

The Patient support section of our website offers in-depth resources to help demystify radiotheranostics, by detailing how they work, their clinical applications, where to receive treatment and through shared patient stories. Whether you're seeking to learn more about the science behind these treatments or looking for practical insights, our education hub is designed to make cutting-edge knowledge accessible to everyone, helping to raise awareness about radiotheranostics options in the fight against cancer.



 <b>Breast Cancer</b>	 <b>Bone Cancer &amp; Pain Palliation</b>	 <b>Female Cancer</b>	 <b>Gastrointestinal Cancer</b>	 <b>Glioblastoma and Brain Cancer</b>
 <b>Head and Neck Cancer</b>	 <b>Hepatocarcinoma</b>	 <b>Kidney Cancer</b>	 <b>Leukemia</b>	 <b>Lymphoma</b>
 <b>Skin Cancer</b>	 <b>Neuroendocrine Tumors (NETs)</b>	 <b>Prostate Cancer</b>	 <b>Thyroid Cancer</b>	 <b>Others</b>

**More patient education leads to improved access**



# Guidance for People Living with Cancer

## Mister Bind and his Companions





Numerous discussions with nuclear medicine practitioners revealed a significant need for support explaining the technology to newly diagnosed cancer patients. We have developed an interactive support tool that could address this need.

This collaboration began with Dr. Jérémie Calais in early 2022. With the help from various experts, we created and published two educational videos featuring Mr. Bind and his companions, engaging characters who simplify radiotheranostics for patients.



**Dr. Jeremie Calais**  
MD, PhD, Associate Professor, USA



**PART 1**  
What are radiotheranostics for cancer care?  
> [Watch on YouTube @oncidiumfoundation9833](#)



**PART 2**  
Doctor, will radiotheranostics make me radioactive?  
> [Watch on YouTube @oncidiumfoundation9833](#)

We also decided to transform the videos into a more tangible format by creating a patient follow-up notebook. Given Belgium's renowned comic strip tradition, a comic book was the ideal medium. Since its launch in 2023, the Mr. Bind comic book has encountered significant success, reaching not only patients and the nuclear medicine community but also the general public.

We have distributed thousands copies of Mr. Bind worldwide, available in five languages and ten more languages will be available in 2025.

The adventures of Mr. Bind will certainly continue! The Oncidium team, along with other experts, are already hard at work on the book's next edition.

**Stay tuned!**



“The comic book “Mr. Bind” could play a pivotal role in this mission by simplifying the complexities of radioligand therapy, making the information more accessible and engaging for patients. By using visual storytelling, “Mr. Bind” can demystify the treatment process, helping patients feel more informed and at ease.”

**Prof. Loïc Djaïleb**  
MD, PhD, Head of the Nuclear Medicine Department at CHU Grenoble Alpes

# Guidance for People Living with Cancer

## RLT Channel

### Episode 1: Prostate Cancer's New Hope: RLT in Action - Global and Belgium focus

This first episode of the RLT Channel series is designed for individuals living with prostate cancer and their loved ones.

Its goal is to demystify radioligand therapy (RLT) by offering clear and practical information, helping you understand how the therapy works, its potential benefits, and how it can be integrated into the care pathway.



### RLT Channel: Bringing Radiotheranostics to the Forefront of Cancer Care

The RLT Channel is evolving into one of our key initiatives, offering a recurring platform to spotlight various cancers and explore their treatment possibilities through radiotheranostics. Each program is designed to provide comprehensive insights, from addressing global challenges to highlighting local perspectives and advancements.

Our upcoming episode will focus on neuroendocrine tumors (NET), examining the latest developments and challenges on a global scale while offering a detailed look at the current state of NET care in Belgium.

#### Stay tuned!

We aim to make this resource widely accessible by producing tailored content for countries or communities that express interest. If you would like to bring similar broadcast to your region, we encourage you to contact the foundation directly. Together, we can raise awareness and advance the potential of radiotheranostics worldwide.

# Resources for the Nuclear Medicine Community

## Supporting Healthcare Professionals

We aim to equip healthcare professionals with concise information and educational resources to enhance their understanding of radiotheranostics and keep them abreast of the field's latest developments. We make great efforts to encourage professional connections and establish a global community dedicated to learning and sharing knowledge toward our common goal of improving patient access to these innovative therapies.

## A Complete State of the Current Radiotherapeutics

We offer a comprehensive and up-to-date overview of radiotherapeutic treatments in cancer care. This resource details approved therapies, those that have been discontinued, and those still in development. It is designed to provide healthcare professionals, patients, and caregivers with accessible, clear information about the latest advancements in this field.

With a simple click, users can explore treatment options tailored to specific cancers, facilitating informed decision-making and enhancing collaboration between patients and their healthcare teams.



## A Biannual Review to Explore the World of Radiotheranostics

In Radiotheranostics Today, we present a comprehensive look into the rapidly advancing field of radiotheranostics.

Thanks to our vast network of contributors, we can offer exclusive interviews and detailed articles from leading experts worldwide, showcasing some of the most cutting-edge breakthroughs in radiotheranostics.

## Theranostics Insights

Theranostics Insights is a monthly scientific content series available across our platforms. Each edition features a deep dive into the mechanisms and wide-ranging medical applications of a specific radiopharmaceutical.

Through these publications, we aim to advance dissemination and knowledge of how specific theranostics compounds are being used to save lives.



# Education for Healthcare Professionals

## Patients Take the Stage to Share Their View

Our focus has always been on what matters most – the patient. Every one of our actions is taken with them at heart, especially in discussions and debates.

We emphasize the vital role of those living with cancer, their loved ones, patient advocates, and their entire medical teams, all crucial parts of the equation to develop and improve radioligand therapy.

In recent years, we have organized patient sessions across continents, each with its own realities regarding radiotheranostics availability and access. Despite their differences, they all share a commonality: **patients are the primary stakeholders in their treatment.** By sharing their stories, they shape clinical trials and ensure that healthcare is designed around their expectations and individual realities.

These sessions featured patients and healthcare professionals from various countries, sharing their unique experiences and focusing on:

- Patient education and the promotion of radioligand therapy
- Treatment access and navigating complex healthcare systems
- Treatment journeys with perspectives and insights from those affected by cancer.



Patient Session in Chile, during the 7<sup>th</sup> Theranostics World Congress



Patient Session in Argentina, during the ALASBIMN 2023

**More patient sessions will be organized** as the demand for better access and availability of such treatments persists. Giving our panelists a platform reminds us always to prioritize patient-centered care and continue the pursuit of advancements that address their needs and experiences.



Patient Session in Germany, during the 6<sup>th</sup> Theranostics World Congress

Patient Session in Italy, during the ITANET 2024



*It is all about patients,*  
**Rebecca Lo bue, CEO of the Oncidium foundation**

*Being an ambassador for Oncidium has allowed many patients in our country to access metabolic therapies, which are not accessible to the entire population, whether pediatric or adult.*

**Dr. Maria Bastianello, Ambassador in Argentina**



# Awareness for Healthcare Professionals

We aim to extend our presence into fields like oncology and urology, strengthening our network and improving patient access globally.

2024 has reflected substantial efforts by the Oncidium foundation toward introducing radioligand therapy to a broader audience, particularly within the oncology community. While nuclear medicine professionals are already convinced of the treatment's impact and our foundation's work, we are now committed to positioning it as a viable cancer treatment option for oncologists and urologists, especially for prostate cancer and neuroendocrine tumors (NET) for which the drug has been approved in several countries.

We are actively working to expand our ambassador network by attending events beyond the nuclear medicine field. Notably, in 2024, we participated in the EAU Uro plenary session in France, discussing "Controversies on GU Cancer Staging: Is It Only Imaging?".

We were also present at ASCO (the American Society of Clinical Oncology), the European Cancer Summit, and AIOM (Associazione Italiana di Oncologia).


Our goal is to ensure that radiotheranostics become more widely recognized and utilized, ultimately enabling more patients to benefit from this innovative treatment. These steps mark the beginning of a larger effort to bring radiopharmaceutical therapies into mainstream cancer care, in line with our ongoing commitment to improving patient outcomes.



2024 - IMPLEMENTATION OF RLT-CONNECT IN BRAZIL



2024 - ASCO, UNITED STATES



2024 - EAU, FRANCE

## Upcoming Projects

- Dubai Radiotheranostics Summit  
*On January 29th, 2025*
- RLT Channel  
*Episode 2: NET Cancer Focus*
- Mister Bind and his Companions  
*Chapter 2*
- Tackle Cancer Challenge 2025  
*4th Edition*
- South Africa Conference  
*June 2025*

# Access Education

## 3 Hope

# key pillars




RLT-Connect	42
Supporting Research Projects	44
Tackle Cancer Challenge	48

# Hope

## Changing Lives, One Patient at a Time

As part of our mission to connect patients and healthcare professionals, the foundation collaborates with patients to better understand existing gaps and needs and provide vital resources to navigate the extensive information available. Therapies are continually evolving, making navigation an overwhelming endeavor as the volume of information expands daily.

We aspire to be a supportive bridge, connecting patients to the resources and information they need.



## RLT-CONNECT

A global treatment donation program for patients in financial need.

RLT-Connect is a collaborative platform established by the Oncidium foundation to facilitate access to radioligand therapies (RLT) for cancer patients who cannot afford them as the treatment is not yet reimbursed. The platform connects healthcare practitioners and radioisotope companies that donate radioisotope doses, enabling treatment for patients in financial need. In its first year, RLT-Connect successfully facilitated the administration of 100 doses across six countries. We are now working to expand the program to as many countries as possible.

### Our Goal?

With an ambitious objective to rally stakeholders, we are committed to administering **2,000 RLT doses over the next five years**, advancing access to cancer care.



# Supporting Research Projects


## NOBLE Registry

The NOBLE registry is dedicated to developing an efficient and affordable alternative through SPECT-imaging, allowing many more patients to access a PSMA scan when indicated.

The objective is to generate a data repository – which may inform further development of PSMA-SPECT products for emerging markets.



And even more...



## South Africa (LU.DO)

At the Oncidium foundation, we are dedicated to advancing radiotheranostics in the fight against cancer. In 2024, **we committed to donated the necessary doses of [177Lu] Lu-DOTA-TATE** to a pilot study in South Africa, aiming to **improve outcomes for children with high-risk neuroblastoma (HR-NB)**.

This study evaluates the therapy's potential as an induction treatment alongside standard chemotherapy, focusing on enhancing metastatic remission rates and enabling further local treatments like surgery.

Secondary goals include assessing safety, dosimetry, and healthcare resource impact.

By supporting this initiative, we address global healthcare disparities and expand access to innovative therapies for children. Insights from this project will shape future strategies to integrate radiotheranostics into pediatric oncology care worldwide.

### Our Partners on This Project:

- Antwerp University Hospital, Antwerp, Belgium
- Tygerberg Hospital, Cape Town, South Africa
- Red Cross War Memorial Children's Hospital, Cape Town, South Africa
- Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
- Inkosi Albert Luthuli Academic Hospital, Durban, South Africa
- Stellenbosch University, Cape Town, South Africa





# Supporting Research Projects



At the Oncidium foundation, we proudly support two innovative projects of the Innovative Health Initiative (IHI) and the European Commission focused on advancing Astatine-211 production. Our role emphasizes patient advocacy, leveraging our ambassador network and patient-centered vision. Through these efforts, the Oncidium foundation reinforces its commitment to expanding access to innovative radiotheranostic solutions and improving cancer care globally.

## Accelerate.eu

Accelerate.eu is an ambitious initiative designed to push the boundaries of cancer treatment by harnessing the power of radiotheranostics with the alpha-emitting isotope Astatine-211 (<sup>211</sup>At). This isotope is uniquely suited for targeting aggressive and hard-to-treat cancers, such as pancreatic, breast, and brain cancers, due to its highly potent, short-range radiation, which minimizes damage to healthy tissue.

Accelerate.eu is a collaboration of 17 European institutions from 9 countries, uniting academic and industrial expertise to transform radiotheranostic therapy. It aims to expand access to next-generation treatments and set new standards in personalized cancer care.




## Thera4Care

Thera4Care is creating a robust, collaborative European ecosystem dedicated to advancing theranostics. This ambitious project unites leading academic centers, healthcare providers, SMEs, and industry stakeholders with the shared goal of preparing healthcare systems for the widespread adoption of theranostic approaches. By establishing an integrated network across Europe, Thera4Care seeks to position Europe as a global leader in this transformative field.

One key focus is on strengthening the manufacturing and supply chains for radiotheranostics and streamlining delivery processes so that treatments reach healthcare facilities with optimized efficiency.

By addressing these foundational needs, Thera4Care is setting the stage for Europe to lead the global landscape in theranostic development and application, ultimately improving outcomes and access for patients across the continent.



# TACKLE CANCER CHALLENGE

3<sup>RD</sup> Edition

The Tackle Cancer Challenge is a virtual sports event where participants can log their kilometres on a mobile app and can interact globally by sharing pictures and raising awareness about radiotheranostics.

This year, we achieved a World Tour (37 000+ km) thanks to our 500+ participants, present in more than 35 countries.

Stay Tuned for the 4th edition in 2025!

3rd edition sponsors



# The Heart of Why We Act

Stories of Hope 52





**Luis,**  
Neuroendocrine tumors

Through resilience and determination, Luis navigated multiple treatments, successfully bringing innovative therapy to Mexico for himself and others. His story emphasizes the importance of hope, the impact of medical advancements, and the strength found in embracing life despite challenges.

“ In 2011, after feeling unwell, I was diagnosed with Neuroendocrine Tumours in my pancreas and liver, receiving a shocking prognosis of only a 3% chance of survival. I chose to focus on that 3% and underwent a surgical procedure, which was successful. During my 35-day recovery, I maintained a positive mindset, visualizing healing energies.

Later, after five tumours were found in my liver, doctors deemed surgery impossible and suggested exploring international treatment options. Determined to bring those options to Mexico, I connected with Dr. Cecilia Carreras, who introduced me to Lutetium-177 Dotatate, a treatment previously only available in Germany. Together, we secured support from local foundations and the National Institute of Nuclear Energy, successfully introducing Lu-177 to Mexico. After receiving the treatment, my tumours were reduced to a molecular level.

My advice to others facing similar challenges is to never lose hope, trust in medical advancements, and embrace life with positivity. Every day is a gift. ”



**Pallab,**  
Neuroendocrine tumors

“ This treatment, made possible through the sponsorship of the Oncidium foundation, has given me renewed hope and strength on this challenging journey.

Under the care of Dr. Swagat Dash at Sarvodaya Hospital, Faridabad, India, I received PRRT on the 21st of October. Dr. Dash helped me a lot throughout the process. The procedure went smoothly, and I am optimistic about the benefits it may bring. I cannot thank you enough for the role your foundation has played in making this life-changing treatment accessible to me. Knowing that organizations like Oncidium foundation exist, dedicated to supporting patients in need, provides immense comfort and encouragement.

Please extend my sincere thanks to everyone involved in your foundation's mission. Your support means the world to me and many others who face similar challenges. I hope to honor this gift by staying hopeful and proactive in my treatment and health journey.

Thank you once again for your compassion, generosity, and commitment to patients like me. I also hope that I will get the necessary support from you in the future ”

“ Suddenly in July, the PSMA showed a terrible spread of the tumor with, lots of abdominal lymph nodes, even a supraclavicular, and an adrenal, much to my surprise once again. And I started looking for a treatment. I consulted an oncologist, then looked on the Internet, and that's when I came across Lutetium. The treatment was quite expensive... Frankly speaking really expensive. Dr. Yeiha suggested to contact the Oncidium foundation.

I received my first dose on September 2, 2024, a month ago today. **It was simply wonderful and magnificent, to say the least.**

The little bone pains that had been there have totally disappeared, completely, as if by magic. My mind started to become clearer, and I became mentally more alert. I started to feel hungry and thirsty, and I felt like going out. And that night, above all, I had an extremely peaceful sleep, which hadn't happened to me for at least two years. And all this happened without the slightest side effect.

I also want to thank the Oncidium foundation for their generosity. Without you, none of this would have been possible. ”

**John-Antoine,**  
Prostate Cancer



Let's Talk about Finance 56  
Some Key Figures 58

# Foundation in Numbers



# Let's Talk About Finance

## How are we financed?


The foundation's funding currently comes from:

- Donations from individual, companies and non-profits
- Grants from governmental authorities (mostly European)
- Partnerships with companies from the Nuclear Medicine field

In 2024, thanks to the generosity of our contributors, the Oncidium foundation was able to support many projects around the world. On behalf of those we support, we want to sincerely thank you for your contribution and commitment over the year. Together, we were able to concentrate our efforts at the heart of the fight against cancer!

The following pie chart shows how we allocated this year's contributions between our three pillars (Access, Education, Hope):

## How do we spend our budget?



A substantial portion of our investment is allocated to RLT-Connect to focus on direct patient impact through treatment access.

Investing funds in *meaningful and impactful projects.*

## Why support us?

Together, we can make a profound impact on the lives of countless individuals battling cancer.

By donating to the Oncidium foundation, you will support and enhance:

### Global Impact

Support research, education, and initiatives benefiting patients worldwide.

### Community Engagement

Demonstrate corporate social responsibility by meaningfully engaging your community, employees, and stakeholders.

### Positive Recognition

Your generosity is acknowledged through featured recognition on our website, social media, and events.

Every project we undertake is patient focused and every contribution directly improves patient access to life-saving treatments. 100% of contributions received will go directly to financing such projects.



“ Together, we can create a future where cancer care is more widely available and accessible, all around the world.”

# The Oncidium Foundation...



...in Figures

## Our Path Forward

“ The future holds significant opportunities that fuel our dedication to expanding the impact of radiotheranostics in oncology. While we have already made notable progress, we see our achievements as just the beginning. Our mission to raise awareness of radiotheranostics and improve patient access globally is the guiding force behind our ongoing initiatives and ambitious goals for the future.

Looking ahead, our focus is on solidifying our presence across different oncology sectors and deepening our expertise in nuclear medicine. We recognize oncologists as vital partners in advancing radiotheranostics, and we will work to strengthen our relationships within this community, ensuring that radiotheranostics becomes a cornerstone in cancer care.

**Over the next five years, through RLT-Connect we aim to donate 2,000 treatment doses, directly supporting patients and ensuring that radiotheranostics is accessible to those in need, wherever they are. This initiative will be an essential part of our broader strategy to make radiotheranostics a global standard in cancer treatment.**

To support this project and create more bridges, we have set clear and ambitious objectives, with a key goal of expanding our ambassador network to over 200 ambassadors, ensuring at least one in each country. This will enhance our international and local reach, fostering a global community of advocates for radiotheranostics and improving patient access worldwide. We also plan to establish new subsidiaries, building on our headquarters in Belgium and our recently opened office in the United States.

**Thank you all for your support. Together, let's continue working to improve global patient access to radiotheranostics. ”**

Rebecca Lo bue,  
Chief Executive Officer



Oncidium  
foundation

Access • Education • Hope

### Foundation Partners



Wallonia.be

EXPORT  
INVESTMENT

### RLT Connect Supporters



### Tackle Cancer Challenge



## Contact us

The Oncidium foundation  
Avenue Herrmann-Debroux, 40  
1160 Brussels | Belgium

[www.oncidiumfoundation.org](http://www.oncidiumfoundation.org)  
[contact@oncidium-life.org](mailto:contact@oncidium-life.org)

B.N.: 0838.388.420

